Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2607-2618

  Tavanti, E ^a   Sero, V ^a   Vella, S ^a   Fanelli, M ^a   Michelacci, F ^a   Landuzzi, L ^a   Magagnoli, G ^a   Versteeg, R ^b   Picci, P ^a   Hattinger, C M ^a   Serra, M ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CISPLATIN; DOXORUBICIN; METHOTREXATE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; SMALL INTERFERING RNA; TOZASERTIB;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL MOTILITY; CROSS RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; ANTINEOPLASTIC AGENTS; AURORA KINASES; BENZAMIDES; BONE NEOPLASMS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; PIPERAZINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84887839886     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.643     Document Type: Article

References (38)

1. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A (2007) The role of aurora-A inhibitors in cancer therapy. Ann Oncol 18(Suppl 6): vi47-vi52.
2. Arlot-Bonnemains Y, Baldini E, Martin B, Delcros JG, Toller M, Curcio F, Ambesi-Impiombato FS, D'Armiento M, Ulisse S (2008) Effects of the aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer 15(2): 559-568.
3. Baldini E, Arlot-Bonnemains Y, Sorrenti S, Mian C, Pelizzo MR, De Antoni E, Palermo S, Morrone S, Barollo S, Nesca A, Moretti CG, D'Armiento M, Ulisse S (2011) Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. BMC Cancer 11: 411-423.
4. Barouch-Bentov R, Sauer K (2011) Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 20(2): 153-208.
5. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, Bridge JA, Sorensen P, Thorner P, Squire JA (2003) Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8 17 and 20 in osteosarcomas. Genes Chromosomes Cancer 36(1): 7-16.
6. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P, Scotlandi K (1999) Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80(4): 581-588.
7. Cheung CH, Lin WH, Hsu JT, Hour TC, Yeh TK, Ko S, Lien TW, Coumar MS, Liu JF, Lai WY, Shiao HY, Lee TR, Hsieh HP, Chang JY (2011) BPR1K653 a novel aurora kinase inhibitor exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells. PLoS One 6(8): e23485.
8. Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6(7): 1075-1085.
9. Cohen P (2002) Protein kinases-the major drug targets of the twentyfirst century? Nat Rev Drug Discov 1(4): 309-315.
10. Deep G, Agarwal R (2008) New combination therapies with cell cycle agents. Curr Opin Investig Drugs 9(6): 591-604.
11. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1 Mad2 and Cenp-E to kinetochores. J Cell Biol 161(2): 267-280.
12. Ducat D, Zheng Y (2004) Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 301(1): 60-67.
13. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5(1): 1-10.
14. Ganem NJ, Pellman D (2007) Limiting the proliferation of polyploid cells Cell 131(3): 437-440.
15. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI (2006) The Aurora Kinase Inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66(15): 7668-7677.
16. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q (2007) Aurora-A a negative prognostic marker increases migration and decreases radiosensitivity in cancer cells. Cancer Res 67(21): 10436-10444.
17. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM (2004) VX-680 a potent and selective small-molecule inhibitor of the aurora kinases suppresses tumor growth in vivo. Nat Med 10(3): 262-267.
18. Hassa PO (2009) The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front Biosci 14: 72-111.
19. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M (2010) Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15(4): 615-634.
20. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M (2009) Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48(4): 289-309.
21. Katayama H, Sen S (2010) Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 1799(10-12): 829-839.
22. Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SEA (2012) Pharmacodynamic study of the P-glycoprotein antagonist CBT-1s in combination with paclitaxel in solid tumors. Oncologist 17(4): 512-523.
23. Lens SM, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10(12): 825-841.
24. Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, Qian CN, Resau JH, Kim H, Teh BT (2010) VX680/MK-0457 a potent and selective aurora kinase inhibitor targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2(3): 296-308.
25. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM (2008) Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 466(9): 2168-2175.
26. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R (2012) Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51(1): 10-19.
27. Mountzios G, Terpos E, Dimopoulos MA (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34(2): 175-182.
28. Nair JS, Ho AL, Schwartz GK (2012) The induction of polyploidy or apoptosis by the aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle 11(4): 807-817.
29. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research A trans-European EuroBoNet effort. Genes Chromosomes Cancer 49(1): 40-51.
30. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M (2008) Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68(16): 6661-6668.
31. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)-and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor CBT-1s. Biochem Pharmacol 75(6): 1302-1312.
32. Saeki T, Ouchi M, Ouchi T (2009) Physiological and oncogenic Aurora-A pathway. Int J Biol Sci 5(7): 758-762.
33. Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P (2004) Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15(1): 151-160.
34. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G, Baldini N (1993) Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13(2): 323-329.
35. Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6): 148-152.
36. Ulisse S, Arlot-Bonnemains Y, Baldini E, Morrone S, Carocci S, Di Luigi L, D'Armiento M (2010) Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity. J Endocrinol 204(2): 135-142.
37. Wan XB, Fan XJ, Chen MY, Xu J, Long ZJ, Hua YJ, Ji H, Liu L, Hong MH, Zeng YX, Liu Q (2009) Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma. Cancer Biol Ther 8(15): 1500-1506.
38. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T (2009) Functional genome screen for therapeutic target of osteosarcoma. Cancer Sci 100(12): 2268-2274.